Moshkevich Solomon 4
4 · Natera, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Natera (NTRA) President Solomon Moshkevich Sells Shares
What Happened
Solomon Moshkevich, President, Clinical Diagnostics at Natera (NTRA), sold a total of 4,639 shares in multiple open-market transactions on February 2–3, 2026, for aggregate proceeds of approximately $1,072,539. Individual reported transactions: 80 shares @ $228.50 ($18,280); 878 @ $229.96 ($201,903); 576 @ $230.84 ($132,964); 850 @ $232.33 ($197,477); 600 @ $233.24 ($139,942); 16 @ $234.00 ($3,744); and 1,639 @ $230.77 ($378,229). These were sales (not purchases).
Key Details
- Transaction dates: Feb 2–3, 2026. Report filed Feb 4, 2026 (timely within standard 2‑business‑day window).
- Total shares sold: 4,639; total proceeds reported: ~$1,072,539.
- Reported prices include weighted averages and multiple execution prices; footnotes show sale prices ranged roughly $229.57–$233.82 across lots.
- Footnotes: some sales were executed under a Rule 10b5‑1 trading plan adopted Nov 26, 2024; one sale was to satisfy tax withholding on RSU vesting per the Reporting Person’s Stock Unit Agreement (Jan 31, 2025).
- Shares owned after the transactions: not specified in the provided summary—see the Form 4 for post‑transaction holdings.
Context
Sales by executives can be routine (e.g., planned trading under a 10b5‑1 plan or tax withholding on vested awards) and do not by themselves indicate a company outlook. Here, the filing explicitly notes a 10b5‑1 plan and a tax‑withholding sale for RSUs, which point to planned or administrative reasons for the disposals rather than an ad‑hoc market timing decision.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-02-02$228.50/sh−80$18,280→ 142,406 total - Sale
Common Stock
[F1][F2]2026-02-02$229.96/sh−878$201,903→ 141,528 total - Sale
Common Stock
[F1][F3]2026-02-02$230.84/sh−576$132,964→ 140,952 total - Sale
Common Stock
[F1][F4]2026-02-02$232.33/sh−850$197,477→ 140,102 total - Sale
Common Stock
[F1][F5]2026-02-02$233.24/sh−600$139,942→ 139,502 total - Sale
Common Stock
[F1]2026-02-02$234.00/sh−16$3,744→ 139,486 total - Sale
Common Stock
[F6]2026-02-03$230.77/sh−1,639$378,229→ 137,847 total
Footnotes (6)
- [F1]The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $229.5700 to $230.5150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $230.6150 to $231.1400 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $231.94 to $232.92 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $232.94 to $233.82 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.